- Home
- WERN vs KNSA Comparison
WERN vs KNSA Comparison
Compare WERN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WERN
- KNSA
- Stock Information
- Founded
- WERN 1956
- KNSA 2015
- Country
- WERN United States
- KNSA United Kingdom
- Employees
- WERN N/A
- KNSA N/A
- Industry
- WERN Trucking Freight/Courier Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- WERN Industrials
- KNSA Health Care
- Exchange
- WERN Nasdaq
- KNSA Nasdaq
- Market Cap
- WERN 1.8B
- KNSA 1.9B
- IPO Year
- WERN N/A
- KNSA 2018
- Fundamental
- Price
- WERN $25.97
- KNSA $27.92
- Analyst Decision
- WERN Hold
- KNSA Strong Buy
- Analyst Count
- WERN 12
- KNSA 5
- Target Price
- WERN $31.50
- KNSA $38.80
- AVG Volume (30 Days)
- WERN 923.5K
- KNSA 474.9K
- Earning Date
- WERN 07-29-2025
- KNSA 07-22-2025
- Dividend Yield
- WERN 2.16%
- KNSA N/A
- EPS Growth
- WERN N/A
- KNSA N/A
- EPS
- WERN 0.29
- KNSA N/A
- Revenue
- WERN $2,973,292,000.00
- KNSA $481,166,000.00
- Revenue This Year
- WERN $0.52
- KNSA $37.21
- Revenue Next Year
- WERN $6.30
- KNSA $5.32
- P/E Ratio
- WERN $90.39
- KNSA N/A
- Revenue Growth
- WERN N/A
- KNSA 59.45
- 52 Week Low
- WERN $23.02
- KNSA $17.38
- 52 Week High
- WERN $42.48
- KNSA $28.56
- Technical
- Relative Strength Index (RSI)
- WERN 41.82
- KNSA 65.26
- Support Level
- WERN $25.86
- KNSA $26.58
- Resistance Level
- WERN $26.68
- KNSA $27.90
- Average True Range (ATR)
- WERN 0.60
- KNSA 1.01
- MACD
- WERN -0.03
- KNSA -0.03
- Stochastic Oscillator
- WERN 14.49
- KNSA 89.37
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.